RxDoctor Payments Data

Susan Wright, MD

Internal Medicine · Opelika, ALNPI 1326120031

Payments from drug & device makers

$580in general payments, 2019–2025

Across 37 payments — averaging $15.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$87
  • AbbVie$77
  • Amgen$74
  • Novo Nordisk$45
  • AstraZeneca$35
  • Sanofi-aventis U.S. LLC$30
  • plus $233 from 13 others

What the payments were for

  • Food & beverage$580100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$580 in reported general payments places this provider in the 55th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$125,176
Medicare patients
273
Services billed
1,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$132,504
JardianceEmpagliflozin77$81,675
JanuviaSitagliptin Phosphate71$71,341
MounjaroTirzepatide56$62,697
EliquisApixaban48$61,802
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$28,070
JanumetSitagliptin Phos/Metformin Hcl11$14,938
TrulicityDulaglutide12$13,463
TradjentaLinagliptin20$10,846
Repatha SureclickEvolocumab19$10,254
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$9,553
MyrbetriqMirabegron14$9,464
Raloxifene Hcl101$9,122
FarxigaDapagliflozin Propanediol14$8,773
AbrysvoRsv Vacc, Pref A And Pref B/Pf27$8,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$45$132,504122 claims
MerckJanuvia, Janumet, Dulera$11$89,78193 claims
Lilly USA, LLCMounjaro, Trulicity$26$76,16068 claims
Astellas Pharma US IncMyrbetriq$16$9,46414 claims
AstraZenecaFarxiga$35$8,77314 claims
GSKTrelegy Ellipta$87$7,54512 claims
AbbVieSynthroid$77$3,46726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Opelika

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →